Physician profile
Julio Guzman
NPI 1184653628
$10,691.98
in general payments reported to CMS, 2019-2025
46 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $554 · 2021: $1,692 · 2022: $1,387 · 2023: $2,122 · 2024: $2,144 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,589 · Education: $4.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,588.90 |
| Education | $4.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,437.53 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,230.42 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $910.17 | 2021-2025 | |
| Amgen INC. | $841.38 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $793.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.76 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $694.68 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $461.90 | 2023-2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $460.79 | 2019-2025 | Linzess |
| Xeris Pharmaceuticals, INC. | $334.52 | 2021-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $296.06 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.12 | 2019-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $190.11 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $177.66 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $159.84 | 2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $147.20 | 2022-2024 | |
| Ultragenyx Pharmaceutical INC. | $135.81 | 2021 | |
| Allergan, INC. | $109.90 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $107.51 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.21 | 2025 | Caplyta |
| Ardelyx, INC. | $98.86 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $94.52 | 2023-2024 | Accrufer |
| Glaxosmithkline, LLC. | $87.60 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Sunovion Pharmaceuticals INC. | $71.62 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $71.27 | 2021-2022 | |
| Lundbeck LLC | $68.37 | 2024-2025 | Rexulti |
| Abbott Laboratories | $64.92 | 2021-2023 | Freestyle Libre 3 |
| Smith+Nephew, INC. | $47.45 | 2020-2025 | Collagenase Santyl |
| Amarin Pharma, INC. | $44.79 | 2022-2023 | |
| Dexcom, INC. | $42.90 | 2022-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $41.98 | 2024 | |
| Sanofi-Aventis U.S. LLC | $39.56 | 2019-2023 | |
| Fidia Pharma USA INC. | $38.63 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.03 | 2019 | |
| Corium, LLC | $32.93 | 2023 | Adlarity |
| Exact Sciences Corporation | $32.44 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $31.59 | 2020-2021 | |
| Kyowa Kirin, INC. | $28.62 | 2023 | Crysvita |
| Astellas Pharma US INC | $22.12 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.00 | 2024 | Voquezna |
| Alk-Abello, INC | $20.42 | 2024 | Grastek, Odactra, Ragwitek |
| Almatica Pharma LLC | $18.77 | 2021 | |
| Eisai INC. | $17.69 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.96 | 2025 | |
| Sun Pharmaceutical Industries INC. | $16.00 | 2021 | |
| Merck Sharp & Dohme LLC | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.